OrthoPediatrics Reports Preliminary Q4 & FY2025 Results, Issues FY2026 Revenue and Adjusted EBITDA Guidance
KIDS sits 23% above its 52-week low of $15.28.
Summary
OrthoPediatrics Corp. announced preliminary Q4 and full year 2025 revenue, showing strong growth, and issued positive revenue and Adjusted EBITDA guidance for full year 2026.
Key Events · Earnings and Guidance · KIDS
-
Preliminary Q4 2025 Revenue Reported
The company reported preliminary unaudited total revenue of $61.3 million for the fourth quarter of 2025, representing a 16% increase year-over-year.
-
Preliminary Full Year 2025 Revenue Announced
Preliminary unaudited total revenue for the full year 2025 reached $236.1 million, marking a 15% increase compared to the full year 2024.
-
Issued Full Year 2026 Revenue Guidance
OrthoPediatrics provided full year 2026 revenue guidance in the range of $262.0 million to $266.0 million, projecting an 11% to 13% growth rate.
-
Provided Full Year 2026 Adjusted EBITDA Guidance
The company also guided for approximately $25.0 million in Adjusted EBITDA for the full year 2026.
Analysis · KIDS · Industrial Applications And Services
OrthoPediatrics Corp. has provided preliminary unaudited financial results for the fourth quarter and full year 2025, alongside its full year 2026 guidance. The company reported strong revenue growth for 2025 and projects continued double-digit growth for 2026, indicating a positive operational trajectory. This information is crucial for investors to assess the company's recent performance and future outlook, influencing valuation and investment decisions.
At the time of this filing, KIDS was trading at $18.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $469.7M. The 52-week trading range was $15.28 to $27.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.